Mortality associated with febrile neutropenia has dramatically decreased over the last three decades; a pivotal role has been played by the concept of hospital-based empirical therapy with broad-spectrum combinations of antibiotics. Nevertheless, there is evidence that a subgroup of patients with febrile neutropenia might benefit from less aggressive treatments.
No takes yet. Share an insight, caveat, or question.
Jean Klášterský (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: